WHO Prequalifies First Self Test for Hepatitis C

Self testing for hepatitis C is hoped to increase the rate of patients with the disease that have been officially diagnosed. The agency's goal is to increase the number of people with the disease who have a diagnosis from 36% to 90%.

WHO has prequalified the first hepatitis C self-test, providing “critical support in expanding access to testing and diagnosis” and “accelerating global efforts to eliminate hepatitis C.” Their website has the news.

The product is called OraQuick HCV self-test, manufactured by OraSure Technologies. It is an extension of an HCV rapid antibody test prequalified by WHO in 2017 for professional use, but this new product is “specifically designed for use by lay users.” WHO recommended HCV self-testing in 2021.

National-level HCV self-testing implementation projects have shown “high levels of acceptability and feasibility.” As of the end of 2022, only 36% of the 50 million people living with hepatitis C had been diagnosed and only 20% “have received curative treatment.” This product will hopefully “provide a safe and effective way to expand HCV testing and treatment services.”

The product went through WHO’s prequalification (PQ) program for in vitro diagnostics (IVDs) to ensure it met quality, safety, and performance standards. Dr. Rogério Gaspar, WHO Director for the Department of Regulation and Prequalification, says that the agency’s goal is for “90% of all people with HCV to be diagnosed.”

About the Author

Matt MacKenzie

Matt MacKenzie

Associate Editor

Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care. 

Sign up for our eNewsletters
Get the latest news and updates